Novo Nordisk A/S gains momentum with FDA approval for Wegovy and strategic pricing. Click for why Novo outshines Eli Lilly ...

As Eli Lilly and Novo Nordisk have been battling it out to gain market share of the growing GLP-1 weight loss market, one ...

U.S. prices for obesity-treatment pills that Eli Lilly and Novo Nordisk aim to launch next year likely will be on par with ...

The launch marked Danish drugmaker Novo Nordisk's debut on the continent, ramping up competition with rival Eli Lilly.

Eli Lilly stock is down 5% this month despite strong Q2 results and raised guidance, as data from a study on the obesity pill ...

Novo Nordisk A/S shares advanced after the drugmaker’s blockbuster weight-loss drug Wegovy received US approval to treat a ...

Eli Lilly has rolled out a prefilled pen version of its weight-loss drug Mounjaro at the same price as vials, aiming to ...

Novo Nordisk A/S’s weight-loss drug Wegovy has received FDA approval to treat a serious form of liver disease, giving the ...

Shares in Novo Nordisk rose on Monday, after it got U.S. approval for its weight-loss drug Wegovy to treat a serious liver ...

LLY's orforglipron study results disappoint, shifting investor focus to Novo Nordisk's bid for first FDA-approved oral ...

Eli Lilly on Thursday released data for its daily obesity pill, orforglipron, which found the medication helped obese or ...